M M Maxwell
Affiliation: Massachusetts General Hospital
- Two approaches to drug discovery in SOD1-mediated ALSWendy J Broom
Day Neuromuscular Research Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Charlestown, MA 02129, USA
J Biomol Screen 11:729-35. 2006..Ultimately, the authors believe that these 2 cell-based assays will provide powerful strategies to identify novel therapies for the treatment of inherited SOD1-associated forms of ALS...
- RNAi applications in therapy development for neurodegenerative diseaseM M Maxwell
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard, Medical School, 114 16th Street, Room 3200, Charlestown, MA 02129, USA
Curr Pharm Des 15:3977-91. 2009..It further describes current applications of RNAi techniques for target identification and validation studies and underscores the importance of this methodology to developing treatments for neurological diseases...
- The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNSMichele M Maxwell
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital, Boston, MA 02115, USA
Hum Mol Genet 20:3986-96. 2011....
- New VAPB deletion variant and exclusion of VAPB mutations in familial ALSJ E Landers
Cecil B Day Laboratory for Neuromuscular Research, Massachusetts General Hospital East, Charlestown, MA, USA
Neurology 70:1179-85. 2008..No additional mutations have been identified...
- Discovery of a novel small-molecule targeting selective clearance of mutant huntingtin fragmentsMyra Coufal
Massachusetts Institute of Technology, Cambridge, MA, USA
J Biomol Screen 12:351-60. 2007..These compounds were subjected to a functional assay, which yielded a lead compound that rescues cells from induced mutant polyglutamine toxicity...
- RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cellsMichele M Maxwell
Day Laboratory for Neuromuscular Research and High Throughput Screening Laboratory, MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA
Proc Natl Acad Sci U S A 101:3178-83. 2004..The present study further supports the therapeutic potential of RNAi-based methods for the treatment of inherited human diseases, including ALS...
- Pharmacological promotion of inclusion formation: a therapeutic approach for Huntington's and Parkinson's diseasesRuth A Bodner
Center for Cancer Research, Massachusetts Institute of Technology, Room E18 505, 77 Massachusetts Avenue, Cambridge, MA 02139, USA
Proc Natl Acad Sci U S A 103:4246-51. 2006....
- Discovery of bioactive small-molecule inhibitor of poly adp-ribose polymerase: implications for energy-deficient cellsStephen M Altmann
Massachusetts General Institute for Neurodegenerative Disease and Harvard Medical School, Department of Neurology, Massachusetts General Hospital, Charlestown, 02129, USA
Chem Biol 13:765-70. 2006..The protective role of PARP1 inhibitors against oxidative stress has been shown in this model system...
- RNAi-mediated Silencing of Mutant Superoxide DismutaseMICHELE MAXWELL; Fiscal Year: 2006..In addition, the therapeutic potential of RNAi will be assessed using viral delivery of shRNA to the spinal cords of mutant SOD1 transgenic mice. ..